Curanex Pharmaceuticals Inc Increase Decrease In Operating Lease Liability
Curanex Pharmaceuticals Inc (CURX) reported Increase Decrease In Operating Lease Liability of -$70.34 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-14
- Curanex Pharmaceuticals Inc increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$34.64K.
- Curanex Pharmaceuticals Inc increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$35.70K.
- Curanex Pharmaceuticals Inc increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$40.86K.
- Curanex Pharmaceuticals Inc increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$15.30K.
- Curanex Pharmaceuticals Inc increase decrease in operating lease liability for fiscal 2025 was -$85.21K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$34.64K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$70.34K 10-Q · filed 2026-08-14 | -$111.20K derived: sum of 3 quarters · filed 2026-08-14 | -$126.50K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$35.70K 10-Q · filed 2026-05-14 | -$76.56K derived: sum of 2 quarters · filed 2026-05-14 | -$91.86K derived: sum of 3 quarters · filed 2026-05-14 | -$106.58K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$40.86K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$56.16K derived: sum of 2 quarters · filed 2026-03-30 | -$70.89K derived: sum of 3 quarters · filed 2026-08-14 | -$85.21K 10-K · filed 2026-03-30 |
| 2025-09-30 | -$15.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | -$30.02K derived: sum of 2 quarters · filed 2026-08-14 | -$44.35K 10-Q · filed 2025-11-17 | |
| 2025-06-30 | -$14.72K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$29.05K 10-Q · filed 2026-08-14 | ||
| 2025-03-31 | -$14.32K 10-Q · filed 2026-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |